Author: Shannon Palus

Sanction for Toronto researchers upheld despite court challenge

Shereen Ezzat
Sylvia Asa
Sylvia Asa

A Toronto hospital network is keeping two researchers’ labs closed even after an Ontario court quashed part of a misconduct finding by the institution.

Some background: After the University Health Network found evidence of falsified data, Sylvia Asa stepped down as Program Medical Director of the Laboratory Medicine Program, the largest hospital diagnostic laboratory in Canada. Due to the investigation, UHN suspended the labs of Asa and her husband Shereen Ezzat. In response, Asa and Ezzat asked an Ontario court to quash the misconduct findings; last month, the court overturned two out of three findings, and asked UHN to reconsider its sanction against the pair.

According to the Toronto Star, on February 4th the UHN notified the researchers that the sanction against them would be upheld, and it would not reopen the researchers’ labs.

The Star spoke to the researcher’s lawyer, Brian Moher who  Continue reading Sanction for Toronto researchers upheld despite court challenge

Don’t perform heart surgery described in retracted paper, says editor

Screen Shot 2016-02-08 at 10.53.50 PMA journal is retracting a paper about a heart surgery technique after discovering the researchers did not have ethics approval to perform a the procedure on 130 patients. What’s more, the local cardiac surgical society had asked the first author to stop using the method in 2004, six years before the study was complete.

The patients in the study had atrial septal defects — a congenital hole in their hearts that allows blood to leak between chambers. The retraction note concludes with the editor in chief advising other surgeons to not use the method to close the hole described in the retracted article, “Long-term assay of off-pump atrial septal defect closure using vena caval inflow occlusion and minimally invasive approaches in 130 cases.”

A concern from a reader unraveled the paper. The retraction note explains how:

Continue reading Don’t perform heart surgery described in retracted paper, says editor

Court dismisses lawsuit by XMRV-chronic fatigue syndrome researcher

mikovitsA California court has dismissed virologist Judy Mikovits’s lawsuit against fourteen people and two Nevada corporations, in part because she failed to submit necessary documents on time.

Mikovits is the author on a now-retracted Science paper suggesting a link between a virus known as XMRV and chronic fatigue syndrome, which has no known cause. She alleged that she was fired from the Whittemore-Peterson Institute for blowing the whistle on her former colleague’s activities, and that the defendants then colluded to imprison and defame her.

The court dismissed her case last Wednesday. According to the court minutes,

Continue reading Court dismisses lawsuit by XMRV-chronic fatigue syndrome researcher

Journal temporarily removes paper linking HPV vaccine to behavioral issues

1-s2.0-S0264410X16X00084-cov150hThe editor in chief of Vaccine has removed a paper suggesting a human papillomavirus (HPV) vaccine can trigger behavioral changes in mice.

The note doesn’t provide any reason for the withdrawal, although authors were told the editor asked for further review.

Two co-authors on the paper — about Gardasil, a vaccine against HPV — have previously suggested that aluminum in vaccines is linked to autism, in research a World Health Organization advisory body concluded was “seriously flawed.”

Approximately 80 million doses of Gardasil were administered in the U.S. between 2006 and 2015. Both the the WHO and the Centers for Disease Control and Prevention have ruled the vaccine to be safe — the CDC, for instance, calls it “safe, effective, and recommended.”

The journal published an uncorrected proof of “Behavioral abnormalities in young female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil” online on January 9th, 2016. In its place now is a note that says:

Continue reading Journal temporarily removes paper linking HPV vaccine to behavioral issues

8th retraction appears for researcher who faked patient records

S00219150An 8th paper has been retracted for Anna Ahimastos, a heart researcher who faked patient records.

It’s the last in a chain of retractions that were the result of an investigation by her former workplace, Baker IDI Heart & Diabetes Institute in Australia. As with the others, she did not agree to the retraction.

The investigation found fabricated patients records in some papers; in other papers, such as the newly retracted 2010 study in Atherosclerosis, the original data source could not be verified.  The latest retraction — “A role for plasma transforming growth factor-β and matrix metalloproteinases in aortic aneurysm surveillance in Marfan syndrome?” — followed up on a previous clinical trial, examining how a blood pressure drug might help patients with a life-threatening genetic disorder.

That previous trial — which also included 17 patients with Marfan syndrome treated with either placebo or perindopril — has been retracted from JAMA; the New England Journal of Medicine has also retracted a related letter.

The latest retraction note conveys similar information to the other perindopril/Marfan syndrome retractions: Continue reading 8th retraction appears for researcher who faked patient records

Johns Hopkins investigation leads to retraction of two lung papers, one highly cited

showCoverImageAn investigation at Johns Hopkins University has uncovered several issues with the figures in two papers on a lung disease linked to smoking, one of which is highly cited.

The American Journal of Respiratory and Critical Care Medicine is retracting both papers, which examine the role of protein NRF2 in chronic obstructive pulmonary disease. But both contain spliced and duplicated figures, among other issues.

Both papers — which share a total of five authors — received an expression of concern in 2014, after the corresponding author noticed anomalies in the figures. That same year, PubPeer commenters had begun raising questions about some of the figures in one of the papers.

A spokesperson for Johns Hopkins declined to say whether the investigation considered if the errors were the result of misconduct.

All authors agreed with the retraction, except for one who couldn’t be located. Here’s more from the retraction note for both papers:

Continue reading Johns Hopkins investigation leads to retraction of two lung papers, one highly cited

Journals retracts three bone papers for duplication by same author

1-s2.0-S0168365907X02700-cov150hA journal is Journals are retracting three papers after a biomaterials researcher duplicated his own work, sometimes using the same figures to describe different experiments.

Two of the papers are on bone regeneration; one is about targeting tumors. In addition to issues with figures, two one of the retraction notes explain that the papers contain “widespread plagiarism of text” from other papers by the researcher, Hossein Hosseinkhani.

Hosseinkhani is currently affiliated with the National Taiwan University of Science and Technology; when he did the work in the now retracted papers, published in 2004 and 2007, he was based at Kyoto University Hospital and then National Institute for Materials Science in Japan.

The Journal of Controlled Release published all three two of the papers. Here’s the retraction note for “Bone regeneration through controlled release of bone morphogenetic protein-2 from 3-D tissue engineered nano-scaffold,” which has been cited 118 times, according to Thomson Scientific’s Web of Knowledge.

Continue reading Journals retracts three bone papers for duplication by same author

Investigation leads to 5th retraction for drug researcher

Screen Shot 2016-01-26 at 6.05.21 PMA pharmaceutical researcher has received his fourth and fifth retractions for duplicating papers.

Last we saw Giuseppe Derosa on this blog, he was notching retractions after publishing results from the same clinical trial in six different papers; as part of that fallout, a journal has pulled a fourth paper associated with the trial.

Here’s the note for “Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies,” which has been cited twice, according to Thomson Scientific’s Web of Knowledge:  Continue reading Investigation leads to 5th retraction for drug researcher

Journal retracts nanoparticles paper for duplicating figures

no spine minimum. full size. Editor: Ann Meares JEM: Diane RTP: Jill Kessler

A paper on nanoparticles that target cancer cells has been retracted for duplicating figures from three other papers.

The articles all share a first author: Manasmita Das, based at the time of the research at the Indian Institute of Technology Kharagpur and the National Institute of Pharmaceutical Education and Research (NIPER). According to her LinkedIn profile, she is currently a postdoc at the University of North Carolina.

The abstract of the 2011 Bioconjugate Chemistry paper explains just what the new nanoparticles would be useful for:

Multifunctional nanoparticles, developed in the course of the study, could selectively target and induce apoptosis to folate-receptor (FR) overexpressing cancer cells with enhanced efficacy as compared to the free drug. In addition, the dual optical and magnetic properties of the synthesized nanoparticles aided in the real-time tracking of their intracellular pathways also as apoptotic events through dual fluorescence and MR-based imaging.

But according to the retraction note, figure duplications “seriously undermine the conclusions presented in the research article.” Here’s more about the source of those duplications from the full note: Continue reading Journal retracts nanoparticles paper for duplicating figures

JACS imaging paper “under editorial review”

Screen Shot 2016-01-04 at 2.02.27 PM

The Journal of the American Chemical Society has issued an expression of concern over “the presentation of results” in a 2014 paper about a new probe for use in imaging.

We haven’t heard back from the journal nor the authors of the paper, so there’s not much we can officially say about what the journal is investigating.

Here’s the text from the expression of concern:
 Continue reading JACS imaging paper “under editorial review”